An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial.

Nancy Chan¹, Cerise Tang², Dhruva Biswas², Jungkyu Park², Ken G Zeng², Joseph Cappadona², Chuwen Liu², Alec McClean², Jeroen Berrevoets², Linus Bao², Bartosz Machura², Robert J Gray³, Victoria Wang⁴, Jan Witowski², Krzysztof J Geras², Joseph A Sparano⁵,

¹NYU Langone Laura and Isaac Perlmutter Cancer Center New York, NY United States.

²Ataraxis AI.

³Biostatistics and Computational Biology, Dana-Farber Cancer Institute.

⁴ECOG-ACRIN Biostatistical Center, Dana-Farber Cancer Institute, Boston, MA, USA.

⁵Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: The prescribing of adjuvant chemotherapy for patients with breast cancer must balance the survival benefit against treatment-related toxicities. TAILORx, a phase 3 randomized clinical trial, demonstrated that endocrine therapy alone was, on average, noninferior to chemoendocrine therapy for patients classified as intermediate risk by a 21-gene Recurrence Score (RS) assay. Uncertainty r…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.